Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Profiles
-
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274☆
Galsky, M. D., Gschwend, J. E., Milowsky, M. I., Schenker, M., Valderrama, B. P., Tomita, Y., Bamias, A., Lebret, T., Shariat, S. F., Park, S. H., Agerbaek, M., Jha, G., Stenner, F., Ye, D., Giudici, F., Connors, J., Gupta, S., Chhibber, A., Zhang, J. & Bajorin, D. F. & 1 others, , Jan 2026, In: Annals of Oncology. 37, 1, p. 69-78 10 p.Research output: Contribution to journal › Article › peer-review
Open Access7 Scopus citations -
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial
Fizazi, K., Saad, F., Alonso-Gordoa, T., Żurawski, B., Barthélémy, P., Voog, E., Javier Cutuli, H., Buchler, T., Ye, D., Castellano, D., Kwiatkowski, M., Arslan, C., Richardet, M., Alifrangis, C., Goh, J. C., Vianna, K., Han, W., Hatano, K., Todenhöfer, T. & Retz, M. & 8 others, , Jan 2026, In: Lancet Oncology. 27, 1, p. 68-78 11 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Risk-adapted Prostate Cancer Screening Achieves Mammography-like Benefits: Evidence and Implications for Europe
Carlsson, S. V., Krilaviciute, A., Al-Monajjed, R., Seibold, P., Kuczyk, M., Gschwend, J. E., Debus, J., Antoch, G., Schimmöller, L., Schlemmer, H. P., Kristiansen, G., Kaaks, R., Becker, N. & Albers, P., Mar 2026, In: European Urology. 89, 3, p. 193-195 3 p.Research output: Contribution to journal › Editorial
1 Scopus citations